MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials ...

Dr. Hajjar is an internationally renowned scientific leader in the field of cardiac gene therapy. His laboratory had validated a number of cardiac targets that led to the initiation and completion under his guidance of First-inHuman gene therapy trials in patients with heart failure. He has initiated multiple clinical trials in gene therapy for a variety of cardiovascular diseases. About Longeveron Inc. Investor Contact: Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com "I am deligh ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the transaction for its ongoing clinical and regulatory development of Lomecel-B™ for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes. This press release does not constitute an offer to sell or a solicitation of an offer to buy ...

In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company issued new unregistered warrants to purchase up to an aggregate of 3,395,782 shares of Class A common stock. The new warrants are immediately exercisable at an exercise price of $2.50 per share and have a term of twenty-four months from the date of issuance. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. T ...

Details for the Company's participation: About Longeveron Inc. Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that it will participate in the Virtual Life Sciences Investor ...

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in Apr ...

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in Apr ...

Core Insights - Longeveron (NASDAQ:LGVN) stock is experiencing a significant rally due to positive trial news from the ongoing Phase 2 trial of Lomocel-B, a treatment for hypoplastic left heart syndrome (HLHS) [1][2][4] Group 1: Trial Progress and Investor Sentiment - The Phase 2 trial of Lomocel-B is ongoing, with a positive investigator meeting, indicating strong demand for the product as HLHS is often fatal and requires multiple surgeries [2] - Following the initial announcement of the investigator data, LGVN stock surged by 120.7%, with heavy trading volume of approximately 65.3 million shares, significantly above the daily average of 3.3 million shares [3][4] Group 2: Stock Performance - As of Thursday morning, LGVN stock is up 45.9%, with over 17.5 million shares traded, suggesting potential for continued upward momentum throughout the trading day [5]

In fact, as I'm writing this, LGVN stock has already more than doubled on the day. Indeed, as is the case with most such moves in the biotech sector, investors would be right to assume some sort of key headline around one of the company's prospective drugs is driving the tape. LGVN Stock Rockets Higher on Positive Update HLHS is often fatal and is the result of an undeveloped or absent left ventricle at birth. Reconstructive surgeries are needed to allow the right ventricle to do all the work, but given the ...

Longeveron's lead investigational therapeutic candidate is Lomecel-B™, a proprietary, scalable, allogeneic, adult human bone marrow-derived medicinal signaling cell therapy. ELPIS II is enrolling 38 pediatric patients, with enrollment completion anticipated by year end 2024. The clinical trial is being conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through grants from the National Institutes of Health (NIH). ELPIS II builds on the positive clinical results of ELPIS I. ...